{"organizations": [], "uuid": "59e629fab81492bda28cae952849753499490d35", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-mylan-to-acquire-the-global-market/brief-mylan-to-acquire-the-global-marketing-rights-to-glatiramer-acetate-product-through-an-investment-and-partnership-with-israeli-company-mapi-pharma-idUSASC09VDR", "country": "US", "domain_rank": 408, "title": "BRIEF-Mylan To Acquire The Global Marketing Rights To Glatiramer Acetate Product Through An Investment And Partnership With Israeli Company Mapi Pharma", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-10T14:36:00.000+03:00", "replies_count": 0, "uuid": "59e629fab81492bda28cae952849753499490d35"}, "author": "", "url": "https://www.reuters.com/article/brief-mylan-to-acquire-the-global-market/brief-mylan-to-acquire-the-global-marketing-rights-to-glatiramer-acetate-product-through-an-investment-and-partnership-with-israeli-company-mapi-pharma-idUSASC09VDR", "ord_in_thread": 0, "title": "BRIEF-Mylan To Acquire The Global Marketing Rights To Glatiramer Acetate Product Through An Investment And Partnership With Israeli Company Mapi Pharma", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "mylan nv", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "mylan", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News April 10, 2018 / 11:37 AM / Updated 5 minutes ago BRIEF-Mylan To Acquire The Global Marketing Rights To Glatiramer Acetate Product Through An Investment And Partnership With Israeli Company Mapi Pharma Reuters Staff 1 Min Read \nApril 10 (Reuters) - Mylan NV: \n* MYLAN TO ACQUIRE THE GLOBAL MARKETING RIGHTS TO A ONCE-MONTHLY GLATIRAMER ACETATE PRODUCT THROUGH AN INVESTMENT AND PARTNERSHIP WITH ISRAELI COMPANY MAPI PHARMA \n* CO, MAPI PHARMA TO PARTNER ON DEVELOPMENT & COMMERCIALIZATION OF GA DEPOT, A LONG-ACTING GLATIRAMER ACETATE PRODUCT Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-10T14:36:00.000+03:00", "crawled": "2018-04-10T14:55:43.013+03:00", "highlightTitle": ""}